PRESS RELEASES

Altasciences is proud to announce they have been awarded a 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category.

Altasciences is proud to have supported Metsera, Inc., a clinical stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, on its nonclinical and early-stage clinical trials.

Altasciences is committed to providing world-class bioanalytical services in support of the preclinical and clinical studies conducted at our cutting-edge facilities, as well as extensive standalone solutions to meet your diverse needs. Our flexible bioanalytical services from discovery to Phase IV empower our clients across every phase of research.

Altasciences is proud to announce that Dr. Beatrice Setnik, PhD, has been honored as a PharmaVoice 100 winner.

Altasciences has been recognized in contract research with a 2024 CRO Leadership Award for Capabilities, marking the ninth year that the company has been deemed a top performer. Read more!

The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing.

Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO. The impressive 8,000-square-foot space features state-of-the-art equipment and forty-eight workbenches, with a vast range of services, including ligand binding assays, flow cytometry, biomarker analysis, and cell culture capabilities.

Virpax Pharmaceuticals Inc. has chosen Altasciences to conduct preclinical studies in support of their new drug, an intranasal spray, GCPQ, under the trade name, AnQlar. Click to read more.

Altasciences is pleased to have completed the successful Phase I trial of Ischemix’ novel drug candidate, CMX-2043, for the treatment of acute traumatic brain injury (TBI), at our Montréal clinical facility.

Altasciences has been recognized for excellence in contract research with a 2023 CRO Leadership Award for Capabilities. This marks the eighth year that Altasciences, a fully integrated drug development solution company, has been deemed a top performer.